Concepedia

Patrick R. Hagner

PR

Statistics

Publications

32

Citations

1.7K

H-Index

21

Active since

2006

Affiliations

Bristol-Myers Squibb (United States)(Current)

University of Maryland, Baltimore

Bristol-Myers Squibb (Switzerland)

National Institutes of Health

Harvard University

Patrick R. Hagner is an author at Bristol-Myers Squibb (United States) specializing in life sciences, oncology, and molecular oncology.

ORCID

Publications per year

2006–2024

32

Publications

32

Rate of CRL4CRBN substrate Ikaros and Aiolos degradation underlies differential activity of lenalidomide and pomalidomide in multiple myeloma cells by regulation of c-Myc and IRF4

Chad C. Bjorklund, Ling Lu, Jian Kang et al. · Blood Cancer Journal · 2015 · 217 citations · Full text

, , +17

CC-122, a pleiotropic pathway modifier, mimics an interferon response and has antitumor activity in DLBCL

Patrick R. Hagner, Hon‐Wah Man, Celia Fontanillo et al. · Blood · 2015 · 200 citations · Full text

, , +14

A Phase 2/3 Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Lenalidomide Versus Investigator's Choice in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Myron S. Czuczman, Marek Trněný, Andrew Davies et al. · Clinical Cancer Research · 2017 · 164 citations · Full text

, , +17

Post-transcriptional gene regulation by HuR promotes a more tumorigenic phenotype

Krystyna Mazan-Mamczarz, Patrick R. Hagner, Sharon Corl et al. · Oncogene · 2008 · 110 citations · Full text

, , +11

A First-in-Human Study of Novel Cereblon Modulator Avadomide (CC-122) in Advanced Malignancies

Drew Rasco, Kyriakos P. Papadopoulos, Michael Pourdehnad et al. · Clinical Cancer Research · 2018 · 97 citations

, , +17

1–5 of 32